AU2021350424A1 - Compounds and methods for treating pain - Google Patents

Compounds and methods for treating pain Download PDF

Info

Publication number
AU2021350424A1
AU2021350424A1 AU2021350424A AU2021350424A AU2021350424A1 AU 2021350424 A1 AU2021350424 A1 AU 2021350424A1 AU 2021350424 A AU2021350424 A AU 2021350424A AU 2021350424 A AU2021350424 A AU 2021350424A AU 2021350424 A1 AU2021350424 A1 AU 2021350424A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
pain
subject
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021350424A
Other languages
English (en)
Other versions
AU2021350424A9 (en
Inventor
Tharani CHESSELL
Richard Jenkins
Thor OSTENFELD
Keith Tan
Fraser Welsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2021350424A1 publication Critical patent/AU2021350424A1/en
Publication of AU2021350424A9 publication Critical patent/AU2021350424A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021350424A 2020-09-28 2021-09-27 Compounds and methods for treating pain Abandoned AU2021350424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084358P 2020-09-28 2020-09-28
US63/084,358 2020-09-28
PCT/EP2021/076524 WO2022064043A1 (en) 2020-09-28 2021-09-27 Compounds and methods for treating pain

Publications (2)

Publication Number Publication Date
AU2021350424A1 true AU2021350424A1 (en) 2023-06-01
AU2021350424A9 AU2021350424A9 (en) 2025-01-16

Family

ID=78085879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021350424A Abandoned AU2021350424A1 (en) 2020-09-28 2021-09-27 Compounds and methods for treating pain

Country Status (11)

Country Link
US (1) US20240026036A1 (https=)
EP (1) EP4217388A1 (https=)
JP (1) JP2023543005A (https=)
KR (1) KR20230084199A (https=)
CN (1) CN117279942A (https=)
AU (1) AU2021350424A1 (https=)
BR (1) BR112023004840A2 (https=)
CA (1) CA3195380A1 (https=)
IL (1) IL301548A (https=)
TW (1) TW202228768A (https=)
WO (1) WO2022064043A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2975521A1 (en) 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
EP2298345A3 (en) 2005-01-24 2012-03-21 MedImmune Limited Specific binding members for NGF
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
MX2010001395A (es) 2007-08-10 2010-03-10 Regeneron Pharma Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano.
EP2238154B1 (en) 2008-01-18 2015-09-16 Bio-Rad Laboratories, Inc. Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
US9580509B2 (en) 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
LT3099713T (lt) * 2014-02-02 2020-07-10 Medimmune Limited Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno
FI3863647T3 (fi) * 2018-10-10 2024-03-01 Paradigm Biopharmaceuticals Ltd Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla

Also Published As

Publication number Publication date
IL301548A (en) 2023-05-01
EP4217388A1 (en) 2023-08-02
CN117279942A (zh) 2023-12-22
BR112023004840A2 (pt) 2023-04-18
JP2023543005A (ja) 2023-10-12
WO2022064043A1 (en) 2022-03-31
KR20230084199A (ko) 2023-06-12
TW202228768A (zh) 2022-08-01
CA3195380A1 (en) 2022-03-31
US20240026036A1 (en) 2024-01-25
AU2021350424A9 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
AU2020230316B2 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
WO2019148405A1 (zh) IL-4Rα抗体及其用途
US20210009671A1 (en) Compounds and methods for treating pain
US20240026036A1 (en) Compounds and methods for treating pain
RU2788122C2 (ru) Химерный белок, составленный из домена антагониста NGF и домена антагониста TNFα
HK40028980A (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
HK1231905B (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
HK1231905A1 (en) Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
BR112016017698B1 (pt) Molécula ligante, polinucleotídeo isolado, vetor, microrganismo transgênico, composição, kit, e, uso de uma molécula ligante

Legal Events

Date Code Title Description
SREP Specification republished
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted